Evidence map›Paper›PMID 27237338›Full record

ArticleClinical colorectal cancer2016

A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry.

Jeffrey J Jones, Bruce E Wilcox, Ryan W Benz, Naveen Babbar, Genna Boragine, Ted Burrell, Ellen B Christie, Lisa J Croner, Phong Cun, Roslyn Dillon and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical colorectal cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Jeffrey J JonesApplied Proteomics, Inc., San Diego, CA.
Bruce E WilcoxApplied Proteomics, Inc., San Diego, CA.
Ryan W BenzApplied Proteomics, Inc., San Diego, CA.
Naveen BabbarApplied Proteomics, Inc., San Diego, CA.
Genna BoragineApplied Proteomics, Inc., San Diego, CA.
Ted BurrellApplied Proteomics, Inc., San Diego, CA.
Ellen B ChristieApplied Proteomics, Inc., San Diego, CA.
Lisa J CronerApplied Proteomics, Inc., San Diego, CA.
Phong CunApplied Proteomics, Inc., San Diego, CA.
Roslyn DillonApplied Proteomics, Inc., San Diego, CA.
Stefanie N KairsApplied Proteomics, Inc., San Diego, CA.
Athit KaoApplied Proteomics, Inc., San Diego, CA.
Ryan PrestonApplied Proteomics, Inc., San Diego, CA.
Scott R SchreckengaustApplied Proteomics, Inc., San Diego, CA.
Heather SkorApplied Proteomics, Inc., San Diego, CA.
William F SmithApplied Proteomics, Inc., San Diego, CA.
Jia YouApplied Proteomics, Inc., San Diego, CA.
W Daniel HillisApplied Minds, Glendale, CA.
David B AgusUSC Norris Westside Cancer Center and USC Center for Applied Molecular Medicine, Beverly Hills, CA.
John E BlumeApplied Proteomics, Inc., San Diego, CA. Electronic address: john@appliedproteomics.com.
Abterra Biosciences (United States) · USApplied Minds (United States) · USUSC Norris Comprehensive Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

introductionColorectal cancer (CRC) testing programs reduce mortality; however, approximately 40% of the recommended population who should undergo CRC testing does not. Early colon cancer detection in patient populations ineligible for testing, such as the elderly or those with significant comorbidities, could have clinical benefit. Despite many attempts to identify individual protein markers of this disease, little progress has been made. Targeted mass spectrometry, using multiple reaction monitoring (MRM) technology, enables the simultaneous assessment of groups of candidates for improved detection performance. MATERIALS AND

methodsA multiplex assay was developed for 187 candidate marker proteins, using 337 peptides monitored through 674 simultaneously measured MRM transitions in a 30-minute liquid chromatography-mass spectrometry analysis of immunodepleted blood plasma. To evaluate the combined candidate marker performance, the present study used 274 individual patient blood plasma samples, 137 with biopsy-confirmed colorectal cancer and 137 age- and gender-matched controls. Using 2 well-matched platforms running 5 days each week, all 274 samples were analyzed in 52 days.

resultsUsing one half of the data as a discovery set (69 disease cases and 69 control cases), the elastic net feature selection and random forest classifier assembly were used in cross-validation to identify a 15-transition classifier. The mean training receiver operating characteristic area under the curve was 0.82. After final classifier assembly using the entire discovery set, the 136-sample (68 disease cases and 68 control cases) validation set was evaluated. The validation area under the curve was 0.91. At the point of maximum accuracy (84%), the sensitivity was 87% and the specificity was 81%.

conclusionThese results have demonstrated the ability of simultaneous assessment of candidate marker proteins using high-multiplex, targeted-mass spectrometry to identify a subset group of CRC markers with significant and meaningful performance.

Indexed as

AdultAgedArea Under CurveBiomarkers, TumorColorectal NeoplasmsEarly Detection of CancerFemaleHumansMaleMass SpectrometryMiddle AgedROC CurveSensitivity and SpecificityBiomarkers, TumorClassificationColorectal cancerMachine learningMass spectrometry, Multiple reaction monitoring

Identifiers

PMID27237338
PMCPMC8961700
OpenAlexW2310178408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.